EVOLUTION PÅ ARBEJDET: Indblik i en refleksivt selvforandrende kultur

Workplace organisation and employee identities are increasingly spiritualised, the author argues. Management issues are no longer phrased in materialist terms, but regarded as matters of personal intent and cultural meaning. Ethnographic fieldwork is a highly suitable, albeit complex way of studying the production of meaning under modern capitalist forms of work organisation. In the late 1990s, the author conducted four years of multi-sited ethnographic fieldwork amongst European and North American management consultants and Human Resources Managers. Drawing on this fieldwork, she discusses the contemporary concern with evolution and growth at work. She argues that a sub-culturally nourished, neo-spiritual cosmology of self-development, individual responsibility and change has grown conspicuous in (post)-industrial societies. Under neo-liberal, globalising forms of production and governance, ideals of timed, efficient self-management, self-reflexivity and internalised economic rationalities have conquered the discourse of organisational behaviour. Work is rearticulated as a spiritual quest and a personally profound calling. The values-based trend is a significant factor in this, demanding that work be personally meaningful. The practical enactment and production of this meaningfulness make up very relevant fields for contemporary ethnographic study. However, the author also notes, classic ethnographic notions are challenged in this kind of study. Ideas of the informant as a constant subject-position and the field as a stable place are challenged, when those under study are managers and employees who strive to move ever faster and become ever more evolved, self-altering - and thus always “new”. &nbsp

ARBEJDSLIVETS INTIMISERING

Særlig siden 1990ere har arbejdslivet været karakteriseret af intimisering og inddragelse af nyåndelige, religiøse og på anden vis transcendente forestillinger om forbedring og evaluering af selvet via påvirkning indefra-og-ud. Artiklen gennemgår eksempler på dette fænomen og fremdrager særlige karakteristika ved den nypuritanske ledelsestænkning i dagens arbejdsliv. Den diskuterer tendensen i lyset af en analogi til den klassiske vækkelsesbevægelse og konkluderer, at der her er tale om et ganske omfattende sociokulturelt fænomen med implikationer for medarbejderens – og ikke mindst lederens egen – selvforståelse og subjektivering, også i privatlivet

Steinar Bryn: Norske Amerika-bilete: Om Amerikanisering av norsk kultur

Steinar Bryn: Norske Amerika-bilete: Om Amerikanisering av norsk kultur Anmeldes af Karen Lisa Goldschmidt Salamo

Small RNAs reveal two target sites of the RNA-maturation factor Mbb1 in the chloroplast of Chlamydomonas

Many chloroplast transcripts are protected against exonucleolytic degradation by RNA-binding proteins. Such interactions can lead to the accumulation of short RNAs (sRNAs) that represent footprints of the protein partner. By mining existing data sets of Chlamydomonas reinhardtii small RNAs, we identify chloroplast sRNAs. Two of these correspond to the 5′-ends of the mature psbB and psbH messenger RNAs (mRNAs), which are both stabilized by the nucleus-encoded protein Mbb1, a member of the tetratricopeptide repeat family. Accordingly, we find that the two sRNAs are absent from the mbb1 mutant. Using chloroplast transformation and site-directed mutagenesis to survey the psbB 5′ UTR, we identify a cis-acting element that is essential for mRNA accumulation. This sequence is also found in the 5′ UTR of psbH, where it plays a role in RNA processing. The two sRNAs are centered on these cis-acting elements. Furthermore, RNA binding assays in vitro show that Mbb1 associates with the two elements specifically. Taken together, our data identify a conserved cis-acting element at the extremity of the psbH and psbB 5′ UTRs that plays a role in the processing and stability of the respective mRNAs through interactions with the tetratricopeptide repeat protein Mbb1 and leads to the accumulation of protected sRNA

CIV Emission and the Ultraviolet through X-ray Spectral Energy Distribution of Radio-Quiet Quasars

In the restframe UV, two of the parameters that best characterize the range of emission-line properties in quasar broad emission-line regions are the equivalent width and the blueshift of the CIV line relative to the quasar rest frame. We explore the connection between these emission-line properties and the UV through X-ray spectral energy distribution (SED) for radio-quiet (RQ) quasars. Our sample consists of a heterogeneous compilation of 406 quasars from the Sloan Digital Sky Survey and Palomar-Green survey that have well-measured CIV emission-line and X-ray properties (including 164 objects with measured Gamma). We find that RQ quasars with both strong CIV emission and small CIV blueshifts can be classified as "hard-spectrum" sources that are (relatively) strong in the X-ray as compared to the UV. On the other hand, RQ quasars with both weak CIV emission and large CIV blueshifts are instead "soft-spectrum" sources that are (relatively) weak in the X-ray as compared to the UV. This work helps to further bridge optical/soft X-ray "Eigenvector 1" relationships to the UV and hard X-ray. Based on these findings, we argue that future work should consider systematic errors in bolometric corrections (and thus accretion rates) that are derived from a single mean SED. Detailed analysis of the CIV emission line may allow for SED-dependent corrections to these quantities.Comment: AJ, in press; 39 pages, 11 figures, 3 table

Unification of Luminous Type 1 Quasars through CIV Emission

Using a sample of 30,000 quasars from SDSS-DR7, we explore the range of properties exhibited by high-ionization, broad emission lines, such as CIV 1549. Specifically we investigate the anti-correlation between L_UV and emission line EQW (the Baldwin Effect) and the "blueshifting" of high-ionization emission lines. The blueshift of the CIV emission line is nearly ubiquitous, with a mean shift of 810 km/s for radio-quiet (RQ) quasars and 360 km/s for radio-loud (RL) quasars, and the Baldwin Effect is present in both RQ and RL samples. Composite spectra are constructed as a function of CIV emission line properties in attempt to reveal empirical relationships between different line species and the SED. Within a two-component disk+wind model of the broad emission line region (BELR), where the wind filters the continuum seen by the disk component, we find that RL quasars are consistent with being dominated by the disk component, while BALQSOs are consistent with being dominated by the wind component. Some RQ objects have emission line features similar to RL quasars; they may simply have insufficient black hole (BH) spin to form radio jets. Our results suggest that there could be significant systematic errors in the determination of L_bol and BH mass that make it difficult to place these findings in a more physical context. However, it is possible to classify quasars in a paradigm where the diversity of BELR parameters are due to differences in an accretion disk wind between quasars (and over time); these differences are underlain primarily by the SED, which ultimately must be tied to BH mass and accretion rate.Comment: 51 pages, 18 figures, accepted by AJ, revised version includes various modifications based on the referee's comment

A Conserved Supergene Locus Controls Colour Pattern Diversity in Heliconius Butterflies

We studied whether similar developmental genetic mechanisms are involved in both convergent and divergent evolution. Mimetic insects are known for their diversity of patterns as well as their remarkable evolutionary convergence, and they have played an important role in controversies over the respective roles of selection and constraints in adaptive evolution. Here we contrast three butterfly species, all classic examples of Müllerian mimicry. We used a genetic linkage map to show that a locus, Yb, which controls the presence of a yellow band in geographic races of Heliconius melpomene, maps precisely to the same location as the locus Cr, which has very similar phenotypic effects in its co-mimic H. erato. Furthermore, the same genomic location acts as a “supergene”, determining multiple sympatric morphs in a third species, H. numata. H. numata is a species with a very different phenotypic appearance, whose many forms mimic different unrelated ithomiine butterflies in the genus Melinaea. Other unlinked colour pattern loci map to a homologous linkage group in the co-mimics H. melpomene and H. erato, but they are not involved in mimetic polymorphism in H. numata. Hence, a single region from the multilocus colour pattern architecture of H. melpomene and H. erato appears to have gained control of the entire wing-pattern variability in H. numata, presumably as a result of selection for mimetic “supergene” polymorphism without intermediates. Although we cannot at this stage confirm the homology of the loci segregating in the three species, our results imply that a conserved yet relatively unconstrained mechanism underlying pattern switching can affect mimicry in radically different ways. We also show that adaptive evolution, both convergent and diversifying, can occur by the repeated involvement of the same genomic regions

Global myeloma research clusters, output, and citations: A bibliometric mapping and clustering analysis

Background: International collaborative research is a mechanism for improving the development of dis-ease- specific therapies and for improving health at the population level. However, limited data are available to assess the trends in research output related to orphan diseases. Methods and Findings: We used bibliometric mapping and clustering methods to illustrate the level of fragmentation in myeloma research and the development of collaborative efforts. Publication data from Thomson Reuters Web of Science were retrieved for 2005-2009 and followed until 2013. We created a database of multiple myeloma publications, and we analysed impact and coauthorship density to identify scientific collaborations, developments, and international key players over time. The global annual publication volume for studies on multiple myeloma increased from 1,144 in 2005 to 1,628 in 2009, which represents a 4

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe